{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:55:27Z","timestamp":1780059327141,"version":"3.54.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jdcr.2025.06.034","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T12:07:26Z","timestamp":1751890046000},"page":"171-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Toxic epidermal necrolysis-like subacute cutaneous lupus erythematosus following pembrolizumab therapy"],"prefix":"10.1016","volume":"63","author":[{"given":"Emma","family":"Marchionni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorian","family":"Belakebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Du-Thanh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdcr.2025.06.034_bib1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40268-020-00320-5","article-title":"Systematic review: monoclonal antibody-induced subacute cutaneous lupus erythematosus","volume":"20","author":"Bolton","year":"2020","journal-title":"Drugs R D"},{"key":"10.1016\/j.jdcr.2025.06.034_bib2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management","volume":"25","author":"Muntyanu","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jdcr.2025.06.034_bib3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/ced.14449","article-title":"De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation","volume":"46","author":"Bui","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"10.1016\/j.jdcr.2025.06.034_bib4","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.autrev.2018.03.016","article-title":"Drug-induced lupus: traditional and new concepts","volume":"17","author":"Vaglio","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jdcr.2025.06.034_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/cei\/uxad036","article-title":"Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy","volume":"212","author":"Hsu","year":"2023","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.jdcr.2025.06.034_bib6","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jaad.2020.10.091","article-title":"Changing spectrum of suspected drugs of epidermal necrolysis: a World Health Organization pharmacovigilance database analysis from 1997-2020","volume":"85","author":"Bettuzzi","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2025.06.034_bib7","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1111\/jdv.17698","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis-like cutaneous lupus erythematosus. A case series with long-term follow-up","volume":"36","author":"Marti-Marti","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdcr.2025.06.034_bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jaad.2023.09.061","article-title":"Anti-SS-A antibody is a potential predictor of severe Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective cohort study","volume":"90","author":"Watanabe","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2025.06.034_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/cup.13059","article-title":"Lupus-like cutaneous reaction following pembrolizumab: an immune-related adverse event associated with anti-PD-1 therapy","volume":"45","author":"Shao","year":"2018","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jdcr.2025.06.034_bib10","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD -1 and PD -L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235251262500298X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235251262500298X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T23:55:48Z","timestamp":1758671748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235251262500298X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":10,"alternative-id":["S235251262500298X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.06.034","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxic epidermal necrolysis-like subacute cutaneous lupus erythematosus following pembrolizumab therapy","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.06.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}